Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LCTX Lineage Cell Therapeutics	$0.47 +0.3%	$0.46	$0.37 ▼ $1.16	$103.86M	1.21	1.31 million shs	531,212 shs
MNMD Mind Medicine (MindMed)	$6.37	$6.12	$4.70 ▼ $10.44	$480.09M	2.52	1.37 million shs	382,454 shs
RNAC Cartesian Therapeutics	$10.05 -1.5%	$12.78	$8.85 ▼ $41.87	$260.67M	0.51	115,899 shs	35,526 shs
TRVI Trevi Therapeutics	$6.44 -0.3%	$6.24	$2.30 ▼ $7.39	$643.31M	0.62	1.17 million shs	290,538 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LCTX Lineage Cell Therapeutics	-1.90%	+8.05%	+0.04%	-26.68%	-59.83%
MNMD Mind Medicine (MindMed)	-1.24%	+0.87%	+17.31%	-25.15%	-24.62%
RNAC Cartesian Therapeutics	-2.30%	-3.50%	-4.40%	-46.09%	-52.45%
TRVI Trevi Therapeutics	-3.73%	-1.98%	+16.01%	+59.26%	+136.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LCTX Lineage Cell Therapeutics	2.2132 of 5 stars	3.5	0.0	2.6	3.3	0.6
MNMD Mind Medicine (MindMed)	1.7343 of 5 stars	3.6	1.0	2.1	0.8	0.6
RNAC Cartesian Therapeutics	1.6358 of 5 stars	3.4	0.0	2.2	3.3	0.0
TRVI Trevi Therapeutics	3.7493 of 5 stars	4.7	2.0	3.5	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LCTX Lineage Cell Therapeutics	3.00	Buy	$4.20	791.34% Upside
MNMD Mind Medicine (MindMed)	3.23	Buy	$25.11	294.21% Upside
RNAC Cartesian Therapeutics	2.75	Moderate Buy	$42.50	322.89% Upside
TRVI Trevi Therapeutics	3.30	Buy	$17.56	172.71% Upside

Current Analyst Ratings Breakdown

Latest LCTX, TRVI, MNMD, and RNAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	MNMD Mind Medicine (MindMed)	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/8/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$41.00 ➝ $40.00
4/9/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $41.00
4/9/2025	RNAC Cartesian Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
4/8/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
3/19/2025	TRVI Trevi Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $20.00
3/19/2025	TRVI Trevi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.50 ➝ $12.50
3/19/2025	TRVI Trevi Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00
3/19/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $24.00
3/14/2025	LCTX Lineage Cell Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
3/14/2025	RNAC Cartesian Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $40.00

(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LCTX Lineage Cell Therapeutics	$8.94M	11.62	N/A	N/A	$0.35 per share	1.35
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$1.90 per share	N/A
RNAC Cartesian Therapeutics	$34.17M	7.63	N/A	N/A	($82.38) per share	-0.12
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.29 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LCTX Lineage Cell Therapeutics	-$21.49M	-$0.12	N/A	N/A	N/A	-230.66%	-30.39%	-19.67%	N/A
MNMD Mind Medicine (MindMed)	-$95.73M	-$1.29	N/A	N/A	N/A	N/A	-47.56%	-35.55%	N/A
RNAC Cartesian Therapeutics	-$219.71M	-$52.83	N/A	N/A	N/A	-510.72%	N/A	-6.03%	N/A
TRVI Trevi Therapeutics	-$29.07M	-$0.45	N/A	N/A	N/A	N/A	-63.31%	-57.06%	N/A

Latest LCTX, TRVI, MNMD, and RNAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	MNMD Mind Medicine (MindMed)	-$0.36	-$0.35	+$0.01	-$0.35	N/A	N/A
5/8/2025	Q1 2025	RNAC Cartesian Therapeutics	-$0.61	-$0.68	-$0.07	-$0.68	$0.69 million	$1.10 million
5/6/2025	Q1 2025	TRVI Trevi Therapeutics	-$0.13	-$0.09	+$0.04	-$0.09	N/A	N/A
3/18/2025	Q4 2024	TRVI Trevi Therapeutics	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
3/6/2025	Q4 2024	MNMD Mind Medicine (MindMed)	-$0.33	-$0.41	-$0.08	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LCTX Lineage Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LCTX Lineage Cell Therapeutics	N/A	2.48	2.48
MNMD Mind Medicine (MindMed)	0.09	9.00	9.00
RNAC Cartesian Therapeutics	N/A	10.70	10.70
TRVI Trevi Therapeutics	N/A	7.38	7.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LCTX Lineage Cell Therapeutics	62.47%
MNMD Mind Medicine (MindMed)	27.91%
RNAC Cartesian Therapeutics	86.95%
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
LCTX Lineage Cell Therapeutics	23.60%
MNMD Mind Medicine (MindMed)	2.45%
RNAC Cartesian Therapeutics	57.90%
TRVI Trevi Therapeutics	24.37%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LCTX Lineage Cell Therapeutics	60	220.42 million	168.40 million	Not Optionable
MNMD Mind Medicine (MindMed)	40	75.37 million	71.68 million	Optionable
RNAC Cartesian Therapeutics	64	25.94 million	10.70 million	Optionable
TRVI Trevi Therapeutics	20	99.89 million	58.13 million	Optionable

LCTX, TRVI, MNMD, and RNAC Headlines

Recent News About These Companies

Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?

May 14 at 11:00 AM | zacks.com

Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript

May 11 at 5:02 AM | seekingalpha.com

Barclays PLC Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 10, 2025 | marketbeat.com

Trevi Therapeutics, Inc.: Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 9, 2025 | finanznachrichten.de

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 9, 2025 | finance.yahoo.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from Analysts

May 9, 2025 | marketbeat.com

Marshall Wace LLP Sells 38,203 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 8, 2025 | marketbeat.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Brokerages

May 7, 2025 | americanbankingnews.com

Trevi Therapeutics (TRVI) Expected to Announce Quarterly Earnings on Tuesday

May 5, 2025 | americanbankingnews.com

Ally Bridge Group NY LLC Lowers Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 4, 2025 | marketbeat.com

Acuta Capital Partners LLC Has $3.18 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 4, 2025 | marketbeat.com

Acorn Capital Advisors LLC Invests $8.24 Million in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 4, 2025 | marketbeat.com

Boothbay Fund Management LLC Takes $387,000 Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 4, 2025 | marketbeat.com

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

May 1, 2025 | prnewswire.com

Trevi Therapeutics (NASDAQ:TRVI) Sees Unusually-High Trading Volume - Here's Why

May 1, 2025 | marketbeat.com

Adage Capital Partners GP L.L.C. Takes Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

April 30, 2025 | marketbeat.com

JPMorgan Chase & Co. Boosts Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

April 30, 2025 | marketbeat.com

XTX Topco Ltd Makes New Investment in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

April 28, 2025 | marketbeat.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Silverarc Capital Management LLC

April 24, 2025 | marketbeat.com

Vivo Capital LLC Boosts Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

April 23, 2025 | marketbeat.com

Trevi Therapeutics management to meet virtually with B. Riley

April 22, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LCTX, TRVI, MNMD, and RNAC Company Descriptions

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$0.47 +0.00 (+0.26%)

As of 01:24 PM Eastern

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Mind Medicine (MindMed) NASDAQ:MNMD

$6.37 0.00 (0.00%)

As of 01:21 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Cartesian Therapeutics NASDAQ:RNAC

$10.05 -0.15 (-1.47%)

As of 01:00 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Trevi Therapeutics NASDAQ:TRVI

$6.44 -0.02 (-0.31%)

As of 01:22 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time